Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

Table 2 Change from baseline at week 16 in health status

	Placebo (n = 514)	Tanezumab 2.5 mg (n = 514)	Tanezumab 5 mg (n = 517)
EQ-5D-5L index value
n	452	480	482
LS mean (SE) change from baseline	0.15 (0.01)	0.18 (0.01)	0.19 (0.01)
Difference in LS means (95% CI)		0.03 (0.01, 0.05)	0.04 (0.01, 0.06)
p value		0.0083	0.0015
EQ VAS
n	452	480	482
LS mean (SE) change from baseline	10.09 (0.84)	11.72 (0.83)	12.58 (0.82)
Difference in LS means (95% CI)		1.63 (−0.40, 3.65)	2.49 (0.47, 4.52)
p value		0.1148	0.0157

Observed data. All patients completed the EQ-5D-5L and EQ VAS. UK value set was used. ANCOVA model with independent variables for Study 1 and Study 2: index joint stratification factor, baseline response to question, baseline diary average pain score, and treatment
ANCOVA Analysis of covariance, CI Confidence interval, LS Least squares, SE Standard error, VAS Visual analog scale

ISSN: 1471-2474